916 SIALYL LEWIS C IS THE POSSIBLE NEW TUMOR MARKER TO DETECT TESTICULAR EMBRYONAL CARCINOMA

Abstract

You have accessJournal of UrologyPenis/Testis/Urethra: Benign & Malignant Disease III1 Apr 2012916 SIALYL LEWIS C IS THE POSSIBLE NEW TUMOR MARKER TO DETECT TESTICULAR EMBRYONAL CARCINOMA Kazuhiko Fujita Kazuhiko FujitaKazuhiko Fujita Izunokuni-city, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1013AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Embryonal carcinoma is a highly malignant component of testicular cancer, however, the sensitive serum tumor marker is not exist. We aimed to discover the new serum marker for the testicular embryonal carcinoma. METHODS 1. We examined the immunohistochemical expression of sialyl Lewis C (SLC) and sialyl Lewis A (SLA) using 50 formalin-fixed paraffin-embedded testicular tumor specimens. 2. Serum SLC and SLA was detected before and after the high orchiectomy for the testicular carcinoma. 3. As normal serum values of SLC and SLA were dependent on the Lewis and secretor genotypes, the genotypes of the each patient were determined. RESULTS 1. We found that SLC was expressed dominantly in only embryonal carcinoma, but not in other testicular carcinoma such as seminoma, yolk sac tumor, and choriocarcinoma. 2. Serum SLC was high in testicular carcinoma including embryonal carcinoma, and SLC normalized in the normal values after the operation. The half time of SLC was found to be 7 days. Serum SLC of the metastatic embryonal carcinoma patients corresponded well to the effect of chemotherapy. 3. Both SLC and SLA were not elevated in other testicular carcinomas. CONCLUSIONS We conclude that SLC is the possible new tumor marker for the testicular embryonal carcinoma. Cases Pathology Genotypes Stage Serum SLC Normal value of SLC Serum SLA Normal value of SLA 1 Emb Le/Le, Se/Se 2b 640 30.2 15.3 16.6 2 Emb Le/le, Se/se2 3 633 22.5 5.3 22.3 3 Emb+Tera Le/Le, Se/se2 1 768 17.2 14 25.2 4 Emb+Tera+Yolk Le/Le, Se/se2 1 156 17.2 4 25.2 5 Emb+Tera+Yolk Le/le, Se/Se 1 360 21.2 2 18 6 Emb+Tera+Yolk Le/le, Se/Se 1 220 21.2 2 18 7 Emb+Yolk Le/le, Se/Se 1 250 21.2 4 18 8 Emb+Tera+Yolk+Sem Le/Le, se/se2 3c 760 23.1 31 61.6 9 Emb+Sem+Yolk Le/le, Se/Se 2b 167 21.2 7 18 © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e373-e374 Peer Review Report Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kazuhiko Fujita Izunokuni-city, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...